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Bexsero Antigen Sequence TypeSerogroup B is the only major disease-associated capsular group of Neisseria meningitidis for which no
protein-polysaccharide conjugate vaccine is available. This has led to the development of multi-
component protein-based vaccines that target serogroup B invasive meningococcal disease (IMD), includ-
ing Bexsero, which was implemented for UK infants in 2015, and Trumenba. Given the diversity of
meningococcal protein antigens, post-implementation surveillance of IMD isolates, including character-
isation of vaccine antigens, is essential for assessing the effectiveness of such vaccines. Whole genome
sequencing (WGS), as realised in the Meningitis Research Foundation Meningococcus Genome Library
(MRF-MGL), provides a rapid, comprehensive, and cost-effective approach to this. To facilitate the surveil-
lance of the antigen targets included in Bexsero (fHbp, PorA, NHBA and NadA) for protective immunity, a
Bexsero Antigen Sequence Type (BAST) scheme, based on deduced peptide sequence variants, was
implemented in the PubMLST.org/neisseria database, which includes the MRF-MGL and other isolate col-
lections. This scheme enabled the characterisation of vaccine antigen variants and here the invasive
meningococci isolated in Great Britain and Ireland in the epidemiological years 2010/11 to 2013/14
are analysed. Many unique BASTs (647) were present, but nine of these accounted for 39% (775/1966)
of isolates, with some temporal and geographic differences in BAST distribution. BASTs were strongly
associated with other characteristics, such as serogroup and clonal complex (cc), and a significant
increase in BAST-2 was associated with increased prevalence of serogroup W clonal complex 11
meningococci. Potential coverage was assessed by the examination of the antigen peptide sequences pre-
sent in the vaccine and epidemiological dataset. There were 22.8–30.8% exact peptide matches to
Bexsero components and predicted coverage of 66.1%, based on genotype-phenotype modelling for
63.7% of serogroup B isolates from 2010/14 in UK and Ireland. While there are many caveats to this esti-
mate, it lies within the range of other published estimates.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Invasive meningococcal disease (IMD), caused by Gram nega-
tive organism Neisseria meningitidis, remains an important cause
of morbidity and mortality worldwide [1]. In high income regions
IMD is normally endemic at low incidence and is associated with
serogroups B, C, W and Y, although higher incidence outbreaks
occur periodically [2]. Protein-polysaccharide conjugate vaccines
have been successfully implemented against the major disease-
associated serogroups in high and low income settings, with the
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the serogroup B capsule and human cell surface polysaccharides,
results in poor immune responses and safety concerns [5]. Conse-
quently, development of ‘group B’ vaccines has concentrated on
sub-capsular antigens, using either outer membrane vesicles, puri-
fied proteins, or both [6]. Bexsero was licensed in Europe in 2014
and by the end of 2015, two vaccines, Bexsero [7] and Trumenba
[8], were licensed in the USA. Bexsero, included in the UK infant
immunisation schedule in September 2015 [9], combines the pro-
tein antigens factor-H binding protein (fHbp), neisserial adhesion A
(NadA), neisserial heparin-binding antigen (NHBA) and PorA with
an outer membrane vesicle from the MeNZBTM vaccine [7,10].
Molecular typing approaches are important for IMD diagnosis in
the absence of a confirmed culture [11,12]; as over half of IMD
cases are diagnosed solely by PCR in the UK [13]. Nucleotide
sequence-based typing of meningococci has many applications
[14], including post-vaccination surveillance, where multilocus
sequence typing (MLST) established that meningococcal C conju-
gate vaccine significantly reduced carriage of the outbreak strain
in the UK population [15]. The application of rapid, cost-effective
bacterial whole-genome sequencing (WGS), achieved with the
Meningitis Research Foundation Meningococcus Genome Library
(MRF-MGL), enables high resolution characterisation of clinical
isolates at >95% of loci simultaneously [16]. Analysis of MRF-MGL
data from 2010/11 onwards, publicly accessible on the PubMLST
database [17], made a major contribution to UK vaccination policy,
by determining that increases in serogroup W IMD in the UK were
due to clonal expansion of an aggressive strain first reported in
South America [18,19].
WGS for disease-causing meningococci in Great Britain and Ire-
land provides detailed information on vaccine antigen sequence
variants and enables inference of vaccine coverage. However,
WGS does not identify the extent of immunological cross-
reactivity of antigens, especially those with similar but distinct
peptide sequences. Therefore, enhanced post-implementation
surveillance of Bexsero currently employs the Meningococcal
Antigen Typing System (MATS) assay, developed to predict strain
coverage of Bexsero [20]. Based on serogroup B IMD isolates,
strain coverage of 73% in England and Wales was predicted [21].
Here, we characterised the diversity and structure among
disease-causing N. meningitidis isolates from the UK and Ireland
over four years (2010/14), defining a reproducible method for typ-
ing Bexsero vaccine antigens. As a demonstration of the utility of
WGS, we developed a model for predicting the likely MATS result
from genotype.2. Materials and methods
2.1. Genome collections
A total of 2016 genomes were analysed, representing all
culture-confirmed cases of IMD for epidemiological years
2010/11 to 2013/14 from Great Britain and Ireland: England
(n = 1602); Wales (n = 120); Scotland (n = 114); Northern Ireland
(n = 47); and Republic of Ireland (n = 133) the latter two grouped
as ‘Ireland’ for analysis. There were 19 non-groupable isolates,
the remainder were serogroups A (n = 1), B (n = 1393), C (n = 88),
E (n = 5), W/Y (n = 4), W (n = 202), X (n = 2), Y (n = 301), and Z
(n = 1). The genomes were hosted on PubMLST Neisseria public
database (http://pubmlst.org/neisseria/). Embedded tools within
PubMLST were used to analyse the presence of Bexsero vaccine
antigens (fHbp, NadA, NHBA and PorA), diversity, association with
clonal complex (cc), geographical and temporal spread.2.2. Implementation and curation of Bexsero Antigen Sequence Type
(BAST) scheme
A curated sequence type scheme for Bexsero antigens was
established within PubMLST.org/neisseria database to provide a
robust, objective method of comparing the vaccine antigens. This
enables easy comparison among datasets collected in different
temporal or geographical regions [22]. Previously established
nomenclatures for each component were used, with every unique
peptide sequence for each Bexsero antigen (fHbp, NHBA, NadA,
PorA-VR1 and PorA-VR2) [23–25] assigned a unique identification
number. Although not included in the MATS assay, PorA-VR1 was
included in the BAST scheme, for additional discrimination among
vaccine antigens. Each unique combination of these peptide
sequences identifiers in an isolate was assigned an arbitrary num-
ber (Bexsero Antigen Sequence Type or BAST) in order of discov-
ery, as sequence types (STs) are assigned in MLST [26]. Assigning
peptide sequence variant numbers was complicated where the
gene sequence encoding an antigen was absent or did not encode
an expressed protein. In the absence of protein expression or func-
tional studies for these loci in all isolates, the most biologically
plausible interpretation of sequence data guided the nomencla-
ture. The allele designation 0 (null) was used where absence of
the locus encoding a protein in an isolate was confirmed. In those
cases where an indel mutation in the nadA gene resulted in the
gene being phase variable ‘off’, the potential NadA peptide identi-
fier for phase variable ‘on’ was used. For genomes with frameshift
mutations in fHbp, NadA, or NHBA that rendered the resultant pro-
tein truncated, peptide designation 0 (null) was assigned.
2.3. Analysis of antigen diversity and recombination
Simpson’s index of diversity (D) assessed the diversity of each
protein, ranging from zero to one, with values nearer one indicat-
ing greater diversity [27,28]. Cramer’s V coefficient measured the
association of vaccine antigens and BASTs with cc and was calcu-
lated using the ‘cramersV’ function in the ‘lsr’ package in R 3.1.1.
[29]. Rarefaction curves of BAST and peptide types were produced
using the ‘rarefaction’ function in the ‘vegan’ package in R. A rar-
efaction curve is created by repeatedly re-sampling at random
from a collection of N individuals and subsequently plotting the
average number of species/types represented by N individuals.
Analysis of recombination in the Bexsero vaccine antigen genes
was carried out using the ClonalFrameML program [30]. ClonalFra-
meML uses a maximum likelihood approach for phylogenetic
reconstruction while taking into account recombination.
2.4. Analysis of population structure
The index of association (IA) determined the level of linkage
equilibrium, the random association of alleles at various loci, in
sequence data [31]. The ‘standardised index of association’, ISA,
detected linkage disequilibrium among the BAST loci using the
START2 program 0.9.0 beta [32,33]. The f⁄ metric measured the
amount of non-overlapping structure in the combinations of anti-
gens [34]. A script written and executed in R calculated the f⁄
metric.
Wrights fixation index, FST, investigated geographic and tempo-
ral structuring. The FST value ranged from zero (no differentiation
among groups, indicative of gene flow), to one (complete differen-
tiation and presence of structure in the population). Significant
genetic differentiation among groups of isolates (years/regions)
and the contribution of geotemporal factors were assessed by
AMOVA [35]. FST and AMOVA were calculated with Arlequin ver-
sion 3.1 [36]. The chi squared test and chi squared test for trend
detected changes in BAST over time and calculated with ‘prop.test’
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R version 3.2.0.
2.5. Genotype-phenotype associations
The BAST scheme is a stable nomenclature that acts as a refer-
ence which can be correlated with functional assays, for example
MATS, which is based on comparison of isolates to reference
strains, not individual serum bactericidal assays [20]. We modelled
a genotype-phenotype association using 508 invasive serogroup B
disease isolates from England and Wales from 2007/08 with previ-
ously published genomic and MATS data [21]. The pilot studies
using BAST genotype alone were not statistically valid in view of
the small sample size (n = 508) and high dimensionality of the
BAST variable alone (217 levels). Instead, the seven MLST loci
(due to associations between cc and BAST) were used with MATS
coverage outcome, based on the presence of at least one antigen
whose relative potency was greater than positive bactericidal
threshold (NadA 0.009, fHbp 0.021, NHBA 0.294) or presence of
PorA-VR2:4 or both [21]. A Projection Pursuit Regression (PPR)
model was employed to address the high dimensionality in
explanatory variables. This was fitted to the data based on overall
coverage outcomes of 0 (not covered) or 1 (covered), using RStudio
Version 0.99.893. To internally validate the PPR model, 10% of data
points were randomly removed and their coverage score predicted,
with 80% accuracy for correct predictions. The PPR model was used
to predict the coverage of STs in the 2007/08 dataset and these
were applied to serogroup B 2010/14 isolates (n = 1393).3. Results and discussion
3.1. BASTs identified in IMD isolates from Great Britain and Ireland
Complete BASTs were assigned to 1966 of the 2016 isolates
(97.5%) with only 50 (2.5%) isolates with incomplete BASTs. Within
the 1966 isolates, 647 BASTs were identified, the nine most fre-
quent accounted for 775 (39.4%) isolates (Fig. 1). A total of 475
BASTs were each represented by single isolates. The most frequent
BAST was BAST-2 (fHbp 22; NHBA 29; NadA 6; PorA-VR 1:5; VR
2:2), which accounted for 137 (7.0%) isolates. Each of the vaccine
components exhibited peptide sequence variation, with fHbp and
NHBA being the two most diverse antigens (Table 1). These data
demonstrate that, although there is high diversity in these antigens
and therefore many BASTs, a limited number of BASTs occur at
high frequency (Fig. S1). Taking into account secular changes, this
indicates that a relatively small number of Bexsero vaccine anti-
gens could achieve high coverage of IMD isolates. There were no
occurrences of BAST-1, an exact match to the vaccine antigens [7].
3.2. Associations of BAST components with clonal complex
There were strong non-overlapping associations between BAST
and cc as determined by MLST [26] (Figs. 2 and S2). For example, all
isolates with BAST-2 (22; 29; 6; 5; 2) (n = 137) and BAST-235 (13;
20; 0; 5–1; 10–8) (n = 10) belonged to cc11. The nine most fre-
quently occurring BASTs were associated with five ccs, with each
cc exhibiting a major BAST (Fig. 2). The association of individual
vaccine antigens and ccs was supported statistically by Cramer’s
V coefficient (Table 1), where values approaching one support an
association with cc.
Such non-random, non-overlapping associations of cc and anti-
gens can be due to clonal descent or immune selection, as pre-
dicted by strain structure models [37,38]. Meningococcal
populations have been shown to have a fundamentally non-
clonal population structure, as a consequence of extensive horizon-tal genetic transfer (HGT) [39]. The effect of recombination events
on a population was measured with ISA, [31], with values ranging
from zero (non-clonal) to unity (clonal). For the whole isolate
collection, ISA was 0.301 consistent with a non-clonal population
dominated by a limited number of dominant, hyperinvasive
lineages.
The overall ISA value in the dataset remained consistent over the
first three years (average = 0.297) but increased to 0.403 in
2013/14, most likely reflecting the increase in W:cc11 associated
BAST-2. When this BAST was removed from the collection the ISA
value decreased to 0.283. This non-random association also held
for all pairwise comparisons of antigens with values ranging from
0.330 for the association of fHbp and PorA-VR2 to 0.735 between
fHbp and NadA. The effects of HGT resulting in intergenic recombi-
nation was detected in each of the antigen genes by ClonalFrame
(Fig. S3(a)–(d)), not discussed further here [30].
The non-overlap in antigen repertoires predicted by strain
structure models was assessed with the f⁄ metric [34]. Values
towards one indicate a non-overlapping structure representing
high cross-immunity amongst antigen variants and immune selec-
tion maintaining antigenic combinations [38], while values
towards zero indicate non-overlapping antigen repertoires and
therefore no cross-immunity amongst antigen variants. Similar to
the ISA values, the pairwise f⁄ metric calculations produced values
ranging from 0.211 for the fHbp and PorA-VR2 pair to 0.614 for
fHbp and NadA. The absence of NadA in 1537/2016 (76.2%) isolates
and restriction to a small number of lineages is likely to account for
the higher ISA and f⁄ metric values compared to the other antigens
comparisons. In addition to being consistent with these antigens
contributing to the development of natural immunity to the
meningococcus, this structure provides an additional means of
assessing potential vaccine coverage. Taken together, the patterns
of variants within the BASTs in this collection, the distribution of
individual antigen variants, and their relationship to cc were con-
sistent with the behaviour of immunodominant antigens in a
recombining population as envisaged in strain structure models,
which supports the use of combinations of these antigens in vac-
cine formulations [34,39].
3.3. Distribution of major BASTs by year and geographical region
There was a similar distribution of the major BASTs for each epi-
demiological year (Fig. 3(a)), with the exception of a significant
increase related to BAST-2 (cc11) (v2 test for trend; p < 0.005)
which increased in proportion from 2.3% (n = 13/569) in 2010/11
to 15.6% (n = 66/422) in 2013/14. In the UK, these meningococci
caused concern due to atypical and severe clinical presentation
[40] and genomic analyses demonstrated their close relationship
to South American W:cc11 isolates [18], leading to the implemen-
tation of vaccines including conjugate serogroup W polysaccha-
rides. Other notable changes in the nine predominant BASTs
were decreases in the two ccs to which most serogroup B strains
belong, from 2010/11 to 2013/14. These were cc269 and associated
BAST-219 which declined from 7.9% (n = 45/569) to 2.6%
(n = 11/422) (v2 test; p < 0.005) and cc41/44 and associated
BAST-220 which declined from 8.3% (n = 47/569) to 4.5%
(n = 19/422) (v2 test; p < 0.05).
There was variation in the geographical distribution of BASTs
(Fig. 3(b)). For example, at the time of sampling BAST-2 was more
prevalent in England (122/1566, 7.8%) and Wales (9/114, 7.9%)
than in either Scotland (2/114, 1.8%) or Ireland (4/174, 2.3%).
BAST-219 ranged in prevalence from 3.4% of isolates in Ireland to
14.0% in Wales. The eighth most common type in the whole
dataset, BAST-225, associated with cc23, was not found in Irish
disease isolates. Pairwise comparisons of the four regions using
FST values obtained from BASTs were different from the null
Fig. 1. Frequency distribution of Bexsero Antigen Sequence Types (BAST) in an invasive meningococcal disease collection (n = 2016) from England, Wales, Scotland,
Northern Ireland and the Republic of Ireland, epidemiological years 2010/11 to 2013/14. (a) Isolates for which the BAST frequency was greater than 5; the x-axis indicates the
BAST, each numbered BAST-2, BAST-219, etc. Each BAST is a unique combination of peptide sequences of the four Bexsero vaccine antigens: factor H-binding protein (fHbp);
Neisseria Heparin Binding Antigen (NHBA); neisseria adhesion protein (NadA) and outer membrane Porin A (PorA). The y-axis is the frequency of each BAST. (b) Isolates for
which the BAST frequency was five or fewer. The x-axis is the number of isolates and the y-axis the frequency of BASTs. Thus, for example, 475 distinct BASTs were
represented by single isolates.
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all regions. It is well-known that the major hyperinvasive ccs
are present worldwide and are stable over time [41,42] but that
their prevalence varies among countries [43,44]. These data
are consistent with a generally stable population of invasive
meningococci, that varies over time, with occasional large
changes in disease incidence caused by the introduction of a novel
clone.3.4. Genotypic matches to the Bexsero vaccine antigens
Isolates were compared at four loci within the vaccine BAST-1,
fhbp:1, NHBA:2, NadA:8 and PorA-VR2:4, as PorA-VR2 is included
in the MATS assay where PorA-VR1 is not [20]. No isolates in the
dataset had an exact match to the vaccine BAST-1. There were
two peptide matches in 74/582 (12.7%) isolates from 2010/11
which reduced to 31/439 (7.1%) in 2013/14 (Fig. 4(a)); however,
Table 1
Bexsero antigen diversity and associations in meningococcal genome collection from Great Britain and Ireland between epidemiological years 2010/11 to 2013/14.
Peptide No. of variants Index of diversity (D) Cramer’s V (association with cc) f⁄ metric Standardised index of association
(95% CIs) fHbp NadA NHBA PorA-VR1 fHbp NadA NHBA PorA-VR1
fHbp 165 0.920 (0.915–0.925) 0.651
NadA 17 0.688 (0.643–0.732) 0.489 0.614 0.735
NHBA 140 0.914 (0.909–0.919) 0.548 0.321 0.521 0.506 0.647
PorA-VR1 39 0.871 (0.864–0.878) 0.716 0.229 0.633 0.255 0.330 0.648 0.380
PorA-VR2 87 0.919 (0.915–0.923) 0.497 0.211 0.492 0.273 0.471 0.345 0.635 0.442 0.597
BAST 647 0.974 (0.971–0.977) 0.946
Fig. 2. Frequency distribution of Bexsero Antigen Sequence Typing (BAST) by clonal complex for the nine most frequently occurring BASTs (n = 775/2016, 39.4%) in invasive
meningococcal disease isolates in the epidemiological years 2010/11 to 2013/14. BASTs shown on the x axis are structured by clonal complex (z axis) for a proportion of
frequently occurring dominant clones circulating in Great Britain and Ireland from 2010/14, for example BAST-2 is only found in isolates of clonal complex 11. Clonal complex
269 has three predominant BASTs, 219, 222 and 267 not found in other clonal complexes.
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vaccine targets is sufficient to protect against disease [45]. Over the
four years, the proportion of isolates with at least one vaccine anti-
gen matching to BAST-1 decreased from 179/582 (30.8%) to
100/439 (22.8%). Predictions based on antigen peptide sequence
alone therefore indicated that a large proportion of disease-
causing isolates would not be covered by the vaccine; however,
this does not take into account the potential contribution to pro-
tection afforded by antigen cross-reactivity.
To account for this, MATS vaccine antigen coverage, which acts
as a proxy based on recombinant antigens, was used to identify
cross-reactive variants. The fHbp variants considered cross-
reactive were: 1.1; 1.4; 1.13; 1.14; 1.15; 1.37; 1.232 [21]. As there
was no correlation between nucleotide sequence variants and rel-
ative potency of NadA, presence of any NadA variant was consid-
ered cross-reactive for the purposes of this estimate. The
presence of PorA-VR1:7-2 was included due to the potential
immunogenicity of this antigen. Due to lack of phenotypic data
regarding the immunogenicity of NHBA variants, this antigen
was excluded from this analysis. The proportion of isolates pos-
sessing at least one cross-reactive vaccine antigen ranged from
58.3% to 60.3% (Fig. 4(b)). We conclude that the remaining 39.7–
41.7% would likely be dependent on protection through antibodies
to NHBA, for which there is a lack of published information.
Vaccine coverage in England and Wales in 2007/2008 was esti-
mated using the MATS assay [21]. This identified 73% (95% CI 57–
87%) of isolates that possessed at least one vaccine antigen exceed-ing the relative potency threshold or presence of PorA-VR P1.4 or
both. Vogel et al., deem this a conservative estimate, owing to lim-
itations imposed by using pooled toddler sera as opposed to adult
or adolescent sera, and lack of consideration of the co-operation
and interactions of minor antigens or those below the positive bac-
tericidal threshold [21]. As the isolates used in this analysis of
BASTs were collected between three and seven years after the time
period for which coverage of 73% was estimated, secular changes in
the bacterial population may contribute to these differences, but it
may also be attributable to differences in the approaches used.
3.5. Genotype-phenotype associations
Using increasingly available WGS, BAST provides a first step in
identifying potential vaccine coverage. As this metric does not take
into account cross-protection and phenotypic expression, it is
important to correlate BAST analysis with functional assays, such
as MATS, and ultimately with disease incidence in immunised
and unimmunised individuals. The latter are more difficult to
quantify robustly, therefore assumptions were made, but these
associations were based on the stable BAST nomenclature. To
demonstrate the potential utility of linking genotype and pheno-
type, published data from 2007/08 [21] was used to fit a PPR model
using the seven MLST loci (given the strong associations between
cc and BAST) and vaccine coverage outcomes (0 = not covered,
1 = covered). The predicted coverage for each ST in 2007/08 was
applied to serogroup B 2010/14 isolates for which an ST was avail-
Fig. 3. Bexsero Antigen Sequence Type (BAST) frequency by epidemiological year and by country/region. (a) Comparison of the relative numbers of BASTs represented by
more than 15 isolates from 1966 meningococcal invasive disease isolates (Great Britain and Ireland) during each of the four epidemiological years 2010/11 (n = 569), 2011/12
(n = 449), 2012/13 (n = 526) and 2013/14 (n = 422). (b) Percentage of BASTs represented by more than 15 isolates from 1966 invasive meningococcal diseases isolates from
England (n = 1566); Ireland (Northern Ireland and the Republic of Ireland; n = 174); Scotland (n = 114) andWales (n = 112). Distinct BASTs are colour coded (see key to right of
main figure; not related to colour coding used in Fig. 2).
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Fig. 4. Bexsero Antigen Sequence Type (BAST) matches to 2016 invasive meningococcal disease isolates in the epidemiological years 2010/11 to 2013/14. (a) All isolates
with exact BAST-1 matches shown by percentage of Bexsero antigen sequence types (BASTs) matching BAST-1 (the antigen profile in the Bexsero vaccine) at up to four loci
(fHbp 1, NHBA 2, NadA 8, PorA VR2 4) by epidemiological years 2010/11 to 2013/14. (b) All isolates with BAST matches to any antigenic variants considered to be cross-
reactive (fHbp variant 1 peptides: 1.1, 1.4, 1.13, 1.14, 1.15, 1.37, 1.232, any NadA peptide variants: NadA-1: 1, 100, 137, 141, NadA-2/3: 2, 3, 4, 6, 7, 8, 121, 127, 130, 131,
NadA-4/5: 21, PorA VR1 7.2), shown by percentage of isolates BASTs matching up to two loci by epidemiological years 2010/11 to 2013/14 (there was only one isolate in
2013/14 with three matches to cross reactive loci).
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coverage could be predicted, the remaining 506 had STs not pre-
sent in 2007/08. For 2010/14, the predicted coverage for individual
epidemiological years ranged from 63.0% to 73.0%. The mean cov-
erage estimate for 2010/14 was 66.1% (95% CI 61.5–70.7%). The
proportion of isolates for which prediction was possible dimin-
ished over the four years; 68.3% in 2010/11 to 51.6% in 2013/14.
In this study, the limitation of using BAST as opposed to ST, was
the variation in number of unique BASTs, 217 in 2007/08 (0.43
BASTs/isolate) which increased to 647 in 2010/14 (0.33 BASTs/iso-
late). As more MATS data becomes available for WGS isolates in
larger datasets, this statistical modelling may become possible.
The difference in coverage for a given ST, as indicated by the MATS
assay, where the host response is assumed to be constant, presum-
ably reflects inter-strain variation in antigen expression. As Bex-
sero surveillance continues, this model therefore provides
predictions controlling for the host immune responses, a poten-
tially added complexity encountered when analysing the impact
of isolates causing disease in vaccinated individuals. It also allows
estimations of vaccine coverage for isolates where STs are already
available in the absence of WGS. For example, the EUMenNet col-
lection (2413 isolates across 17 countries from 2000/2002) [44]
had 1240 isolates for which coverage could be predicted, and
was estimated at 88.8% (95% CI 85.8–91.8%).
4. Conclusions
In this large and representative collection of IMD isolates from
Great Britain and Ireland between 2010/14, we have shown diver-
sity of BASTs, their correlation with genetic structure, and variabil-
ity over time and by geographic region. This analysis demonstrates
a means of achieving rapid and scalable surveillance of isolates
from IMD for Bexsero vaccine antigens. The number of BASTs
not previously present in these regions [21], demonstrated how
the diversity of IMD isolates alters over time; however, a number
of BASTs were relatively stable, W:cc11 associated BAST-2 was
an exception. Based on these analyses, mean estimates of vaccine
coverage were 66.1% (95% CI 61.5–70.7%), but further disease
surveillance occurring in newly vaccinated infants will inform
about cross-reactivity and coverage. Finally, BAST provides a tool
for studying the distribution of vaccine antigens present in the
stable and persistent ccs in any population, presenting the oppor-
tunity for reformulation of the current Bexsero vaccine if and
when required.
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